Sitemap > News > GenitoUrinary Tract Disorders
Displaying 1 - 50 of 60 results
- Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
- King Pharmaceuticals And Palatin Technologies Announce End-Of-Phase 2 Meeting With FDA For Bremelanotide
- Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
- Positive Trial Results - Combination Contraceptive Sprays
- ViaCell Receives IDE Supplement Approval to Advance ViaCyte Pivotal Trial
- Indevus Announces FDA Approval of SANCTURA XR
- MediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
- QuatRx Completes Patient Enrollment In Phase 3 Study Of Ophena™ In Women With Postmenopausal Vaginal Syndrome
- Orexo´s treatment for incontinence/nocturia entering Phase I
- King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
- FDA Announces Revisions to Labels for Cialis, Levitra and Viagra
- FDA Announces Revisions to Labels for Cialis, Levitra and Viagra
- Sciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
- NexMed Confirms FDA Acceptance of NDA for Erectile Dysfunction Product
- Repros\' Lead Product Proellex to Enter Phase 3 for the Treatment of Uterine Fibroid Indications
- Submission of Marketing Authorisation Application for Dapoxetine in Europe
- Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
- Protox Announces Positive Final Results From Bph Study
- FDA Approves Cialis® (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
- Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH
- Vyteris Announces First Successful Non-Invasive Delivery of Peptide Using Smart Patch Technology
- Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
- Nymox Announces Positive Results from New Multi-Center U.S. Study of NX-1207 For BPH
- New Drug Application for Silodosin (Brand name in Japan: Urief) has been filed with FDA.
- Repros\' IND for the Commencement of Phase III Studies of Proellex(R) in the Treatment of Anemia Associated with Uterine Fibroids is Now Effective
- BioSante Pharmaceuticals Initiates Third LibiGel® Phase III Trial in the Treatment of Female Sexual Dysfunction under an SPA
- Æterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
- VIVUS Completes Special Protocol Assessment for Phase 3 Efficacy Studies and Reaches Agreement with the FDA on the Safety Study for Luramist (Testosterone MDTS)
- Urigen Announces Early Closure of URG101 Phase II Clinical Trial based on Positive Interim Analysis Results
- Æterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
- GlaxoSmithKline gains approval for co-administration of Avodart® (dutasteride) with tamsulosin for the treatment of benign prostatic hyperplasia under the European Mutual Recognition Procedure
- Orexo reports positive results from phase I study for OX19
- Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion
- Æterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
- Protox Doses First Patient In Phase 2 BPH Clinical Trial
- NovaBay\'s Lead Aganocide Compound, NVC-422, Well Tolerated in the Bladder in Phase I Trial
- Rexahn Pharmaceuticals Initiates Phase II Trial for Zoraxel
- Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion
- Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene Tablets) Phase 3 Study Related To Treatment Of Symptoms Of Vulvovaginal Atrophy
- Neurocrine Biosciences Completes \'Petal Study\' Treatment Phase for Endometriosis
- Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis
- Repros Therapeutics Inc. Announces That Proellex® Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
- Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial with MPI-676 in Endometriosis
- BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for Expanded Indication of LibiGel in FSD
- FDA Rule and Companion Guidance Make Early Stage Clinical Drug Development Safe and Efficient
- NexMed Receives FDA Response for ED Product
- Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc.
- Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen
- PREGLEM SA INITIATES PHASE III PROGRAM FOR ITS SELECTIVE PROGESTERONE RECEPTOR MODULATOR PGL4001
- Protox Completes Enrollment Of Phase 2 BPH Trial